Dietikon, Switzerland

Thomas Wuest


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2015-2018

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Thomas Wuest: Innovator in Antibody-Cytokine Fusion Proteins

Introduction

Thomas Wuest is a notable inventor based in Dietikon, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-cytokine fusion proteins. With a total of 2 patents, his work focuses on enhancing therapeutic applications through innovative approaches.

Latest Patents

Wuest's latest patents include the invention of site-specific antibody-mediated activation of proapoptotic cytokines, known as AMAIZE. This invention involves antibody-cytokine fusion proteins that possess proapoptotic and immune-modulating properties. The cytokine moiety in these proteins has a bioactivity that is initially very low or limited to specific receptor subtypes. The full biological activity of these reagents is realized only after the antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By carefully selecting the antibody specificity, the cytokine activity can be directed to the tissue that requires treatment, such as tumor tissue. This allows for the production of therapeutic agents that are specifically designed and optimized for particular indications or tumor entities.

Career Highlights

Thomas Wuest is currently associated with BioNTech AG, a leading biotechnology company known for its innovative approaches to cancer treatment and vaccine development. His work at BioNTech AG has positioned him at the forefront of research in antibody-mediated therapies.

Collaborations

Wuest has collaborated with esteemed colleagues in the field, including Klaus Pfizenmaier and Harald Wajant. These collaborations have further enriched his research and contributed to the advancement of therapeutic strategies in biotechnology.

Conclusion

Thomas Wuest's innovative work in antibody-cytokine fusion proteins exemplifies the potential of biotechnology to revolutionize therapeutic approaches. His contributions continue to pave the way for targeted treatments in oncology and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…